Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression

Detalhes bibliográficos
Autor(a) principal: Ayres,Annelise
Data de Publicação: 2020
Outros Autores: Winckler,Pablo Brea, Jacinto-Scudeiro,Laís Alves, Rech,Rafaela Soares, Jotz,Geraldo Pereira, Olchik,Maira Rozenfeld
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Dementia & Neuropsychologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642020000300315
Resumo: ABSTRACT. We investigated the cognitive performance of patients with Myasthenia Gravis (MG) through a cross-sectional study. A battery of cognitive assessments and self-report questionnaires regarding quality of life (QoL), sleep, and depression were applied. The sample consisted of 39 patients diagnosed with MG. The scores showed a predominance of cognitive impairment in the Montreal Cognitive Assessment screening test (MoCA) (66.7%) and in the immediate (59.0%) and recent memory (56.4%) tests. However, after the Poisson regression analysis with robust variance, it was found that patients diagnosed with depression had a prevalence ratio (PR) of 1,887 (CI 1,166‒3,054) for lower MoCA scores, PR=9,533 (CI 1,600‒56,788) for poorer phonemic verbal fluency scores, and PR=12,426 (CI 2,177‒70,931) for the Semantic Verbal Fluency test. Moreover, concerning a decline in short-term memory retention, patients using glucocorticosteroids (GC) and with Beck Depression Inventory scores indicating depression showed PR=11,227 (CI 1,736‒72,604) and PR=0.35 (CI 0.13‒0.904), respectively. No correlation was found between the QoL questionnaire and performance in cognitive tests. We found worse performance in tasks of memory and executive functions in MG patients. These are not associated with the length and severity of the disease. However, a significant prevalence ratio was found for poorer memory performance in patients diagnosed with depression and in those using GC.
id ANCC-1_672957d998fe3ce44a856830294ae404
oai_identifier_str oai:scielo:S1980-57642020000300315
network_acronym_str ANCC-1
network_name_str Dementia & Neuropsychologia
repository_id_str
spelling Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depressionMyasthenia GraviscognitioncognitiveassessmentglucocorticoidsdepressionABSTRACT. We investigated the cognitive performance of patients with Myasthenia Gravis (MG) through a cross-sectional study. A battery of cognitive assessments and self-report questionnaires regarding quality of life (QoL), sleep, and depression were applied. The sample consisted of 39 patients diagnosed with MG. The scores showed a predominance of cognitive impairment in the Montreal Cognitive Assessment screening test (MoCA) (66.7%) and in the immediate (59.0%) and recent memory (56.4%) tests. However, after the Poisson regression analysis with robust variance, it was found that patients diagnosed with depression had a prevalence ratio (PR) of 1,887 (CI 1,166‒3,054) for lower MoCA scores, PR=9,533 (CI 1,600‒56,788) for poorer phonemic verbal fluency scores, and PR=12,426 (CI 2,177‒70,931) for the Semantic Verbal Fluency test. Moreover, concerning a decline in short-term memory retention, patients using glucocorticosteroids (GC) and with Beck Depression Inventory scores indicating depression showed PR=11,227 (CI 1,736‒72,604) and PR=0.35 (CI 0.13‒0.904), respectively. No correlation was found between the QoL questionnaire and performance in cognitive tests. We found worse performance in tasks of memory and executive functions in MG patients. These are not associated with the length and severity of the disease. However, a significant prevalence ratio was found for poorer memory performance in patients diagnosed with depression and in those using GC.Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento2020-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642020000300315Dementia & Neuropsychologia v.14 n.3 2020reponame:Dementia & Neuropsychologiainstname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)instacron:ANCC10.1590/1980-57642020dn14-030013info:eu-repo/semantics/openAccessAyres,AnneliseWinckler,Pablo BreaJacinto-Scudeiro,Laís AlvesRech,Rafaela SoaresJotz,Geraldo PereiraOlchik,Maira Rozenfeldeng2020-09-15T00:00:00Zoai:scielo:S1980-57642020000300315Revistahttp://www.demneuropsy.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||demneuropsy@uol.com.br1980-57641980-5764opendoar:2020-09-15T00:00Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)false
dc.title.none.fl_str_mv Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
title Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
spellingShingle Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
Ayres,Annelise
Myasthenia Gravis
cognition
cognitive
assessment
glucocorticoids
depression
title_short Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
title_full Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
title_fullStr Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
title_full_unstemmed Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
title_sort Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression
author Ayres,Annelise
author_facet Ayres,Annelise
Winckler,Pablo Brea
Jacinto-Scudeiro,Laís Alves
Rech,Rafaela Soares
Jotz,Geraldo Pereira
Olchik,Maira Rozenfeld
author_role author
author2 Winckler,Pablo Brea
Jacinto-Scudeiro,Laís Alves
Rech,Rafaela Soares
Jotz,Geraldo Pereira
Olchik,Maira Rozenfeld
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Ayres,Annelise
Winckler,Pablo Brea
Jacinto-Scudeiro,Laís Alves
Rech,Rafaela Soares
Jotz,Geraldo Pereira
Olchik,Maira Rozenfeld
dc.subject.por.fl_str_mv Myasthenia Gravis
cognition
cognitive
assessment
glucocorticoids
depression
topic Myasthenia Gravis
cognition
cognitive
assessment
glucocorticoids
depression
description ABSTRACT. We investigated the cognitive performance of patients with Myasthenia Gravis (MG) through a cross-sectional study. A battery of cognitive assessments and self-report questionnaires regarding quality of life (QoL), sleep, and depression were applied. The sample consisted of 39 patients diagnosed with MG. The scores showed a predominance of cognitive impairment in the Montreal Cognitive Assessment screening test (MoCA) (66.7%) and in the immediate (59.0%) and recent memory (56.4%) tests. However, after the Poisson regression analysis with robust variance, it was found that patients diagnosed with depression had a prevalence ratio (PR) of 1,887 (CI 1,166‒3,054) for lower MoCA scores, PR=9,533 (CI 1,600‒56,788) for poorer phonemic verbal fluency scores, and PR=12,426 (CI 2,177‒70,931) for the Semantic Verbal Fluency test. Moreover, concerning a decline in short-term memory retention, patients using glucocorticosteroids (GC) and with Beck Depression Inventory scores indicating depression showed PR=11,227 (CI 1,736‒72,604) and PR=0.35 (CI 0.13‒0.904), respectively. No correlation was found between the QoL questionnaire and performance in cognitive tests. We found worse performance in tasks of memory and executive functions in MG patients. These are not associated with the length and severity of the disease. However, a significant prevalence ratio was found for poorer memory performance in patients diagnosed with depression and in those using GC.
publishDate 2020
dc.date.none.fl_str_mv 2020-09-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642020000300315
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642020000300315
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1980-57642020dn14-030013
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento
publisher.none.fl_str_mv Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento
dc.source.none.fl_str_mv Dementia & Neuropsychologia v.14 n.3 2020
reponame:Dementia & Neuropsychologia
instname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)
instacron:ANCC
instname_str Associação de Neurologia Cognitiva e do Comportamento (ANCC)
instacron_str ANCC
institution ANCC
reponame_str Dementia & Neuropsychologia
collection Dementia & Neuropsychologia
repository.name.fl_str_mv Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)
repository.mail.fl_str_mv ||demneuropsy@uol.com.br
_version_ 1754212932357455872